請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64637
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張百恩 | |
dc.contributor.author | Wan-Chih Hsieh | en |
dc.contributor.author | 謝宛芝 | zh_TW |
dc.date.accessioned | 2021-06-16T22:56:48Z | - |
dc.date.available | 2014-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-08-10 | |
dc.identifier.citation | Akimenko, M.A., Mari-Beffa, M., Becerra, J., Geraudie, J., 2003. Old questions, new tools, and some answers to the mystery of fin regeneration. Developmental dynamics : an official publication of the American Association of Anatomists 226, 190-201.
Barrera, P., Blom, A., van Lent, P.L., van Bloois, L., Beijnen, J.H., van Rooijen, N., de Waal Malefijt, M.C., van de Putte, L.B., Storm, G., van den Berg, W.B., 2000. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis and rheumatism 43, 1951-1959. Bayliss, P.E., Bellavance, K.L., Whitehead, G.G., Abrams, J.M., Aegerter, S., Robbins, H.S., Cowan, D.B., Keating, M.T., O'Reilly, T., Wood, J.M., Roberts, T.M., Chan, J., 2006. Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. Nature chemical biology 2, 265-273. Bijvoet, O.L., Nollen, A.J., Slooff, T.J., Feith, R., 1974. Effect of a diphosphonate on para-articular ossification after total hip replacement. Acta orthopaedica Scandinavica 45, 926-934. Bonewald, L.F., Johnson, M.L., 2008. Osteocytes, mechanosensing and Wnt signaling. Bone 42, 606-615. Brozoski, M.A., Traina, A.A., Deboni, M.C., Marques, M.M., Naclerio-Homem Mda, G., 2012. Bisphosphonate-related osteonecrosis of the jaw. Revista brasileira de reumatologia 52, 265-270. Byrjalsen, I., Leeming, D.J., Qvist, P., Christiansen, C., Karsdal, M.A., 2008. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 19, 339-348. Camilleri, J.P., Williams, A.S., Amos, N., Douglas-Jones, A.G., Love, W.G., Williams, B.D., 1995. The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat. Clinical and experimental immunology 99, 269-275. Cartsos, V.M., Zhu, S., Zavras, A.I., 2008. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc 139, 23-30. Catterall, J.B., Cawston, T.E., 2003. Arthritis Research & Therapy 5, 12. D'Aoust, P., McCulloch, C.A., Tenenbaum, H.C., Lekic, P.C., 2000. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell and tissue research 302, 353-363. de Groen, P.C., Lubbe, D.F., Hirsch, L.J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M.J., Pinkas, H., Wang, K.K., 1996. Esophagitis associated with the use of alendronate. The New England journal of medicine 335, 1016-1021. Dominguez, L.J., Di Bella, G., Belvedere, M., Barbagallo, M., 2011. Physiology of the aging bone and mechanisms of action of bisphosphonates. Biogerontology 12, 397-408. Ducy, P., Schinke, T., Karsenty, G., 2000. The osteoblast: a sophisticated fibroblast under central surveillance. Science 289, 1501-1504. Dufourcq, P., Vriz, S., 2006. The chemokine SDF-1 regulates blastema formation during zebrafish fin regeneration. Development genes and evolution 216, 635-639. Dufresne, T.E., Chmielewski, P.A., Manhart, M.D., Johnson, T.D., Borah, B., 2003. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcified tissue international 73, 423-432. Dunn, C.J., Fitton, A., Sorkin, E.M., 1994. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs & aging 5, 446-474. Duque, G., Li, W., Adams, M., Xu, S., Phipps, R., 2011. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 22, 1547-1553. Duque, G., Rivas, D., 2007. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 22, 1603-1611. Fisher, J.E., Rogers, M.J., Halasy, J.M., Luckman, S.P., Hughes, D.E., Masarachia, P.J., Wesolowski, G., Russell, R.G., Rodan, G.A., Reszka, A.A., 1999. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proceedings of the National Academy of Sciences of the United States of America 96, 133-138. Fleisch, H., 1998. Bisphosphonates: mechanisms of action. Endocrine reviews 19, 80-100. Fleisch, H., Russell, R.G., Bisaz, S., Casey, P.A., Muhlbauer, R.C., 1968. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcified tissue research, Suppl:10-10a. Fleisch, H., Russell, R.G., Francis, M.D., 1969. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165, 1262-1264. Fleisch, H., Russell, R.G., Straumann, F., 1966. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212, 901-903. Fleisch, H.A., Russell, R.G., Bisaz, S., Muhlbauer, R.C., Williams, D.A., 1970. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. European journal of clinical investigation 1, 12-18. Fogelman, I., Bessent, R.G., Turner, J.G., Citrin, D.L., Boyle, I.T., Greig, W.R., 1978. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 19, 270-275. Francis, M.D., Russell, R.G., Fleisch, H., 1969. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165, 1264-1266. Frith, J.C., Monkkonen, J., Auriola, S., Monkkonen, H., Rogers, M.J., 2001. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis and rheumatism 44, 2201-2210. Garcia-Moreno, C., Serrano, S., Nacher, M., Farre, M., Diez, A., Marinoso, M.L., Carbonell, J., Mellibovsky, L., Nogues, X., Ballester, J., Aubia, J., 1998. Effect of alendronate on cultured normal human osteoblasts. Bone 22, 233-239. Gasser, A.B., Morgan, D.B., Fleisch, H.A., Richelle, L.J., 1972. The influence of two diphosphonates on calcium metabolism in the rat. Clinical science 43, 31-45. Giuliani, N., Pedrazzoni, M., Negri, G., Passeri, G., Impicciatore, M., Girasole, G., 1998. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22, 455-461. Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., Samonigg, H., Tausch, C., Eidtmann, H., Steger, G., Kwasny, W., Dubsky, P., Fridrik, M., Fitzal, F., Stierer, M., Rucklinger, E., Greil, R., Marth, C., 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. The New England journal of medicine 360, 679-691. Gourion-Arsiquaud, S., Allen, M.R., Burr, D.B., Vashishth, D., Tang, S.Y., Boskey, A.L., 2010. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46, 666-672. Grant, B.T., Amenedo, C., Freeman, K., Kraut, R.A., 2008. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 66, 223-230. Guenther, A., Gordon, S., Tiemann, M., Burger, R., Bakker, F., Green, J.R., Baum, W., Roelofs, A.J., Rogers, M.J., Gramatzki, M., 2010. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. International journal of cancer. Journal international du cancer 126, 239-246. Hewitt, C., Farah, C.S., 2007. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 36, 319-328. Hortobagyi, G.N., Theriault, R.L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J.F., Seaman, J., Knight, R.D., 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. The New England journal of medicine 335, 1785-1791. Idris, A.I., Rojas, J., Greig, I.R., Van't Hof, R.J., Ralston, S.H., 2008. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcified tissue international 82, 191-201. Iovine, M.K., 2007. Conserved mechanisms regulate outgrowth in zebrafish fins. Nature chemical biology 3, 613-618. Jung, A., Mermillod, B., Barras, C., Baud, M., Courvoisier, B., 1981. Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. Cancer research 41, 3233-3237. Kavanagh, K.L., Guo, K., Dunford, J.E., Wu, X., Knapp, S., Ebetino, F.H., Rogers, M.J., Russell, R.G., Oppermann, U., 2006. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proceedings of the National Academy of Sciences of the United States of America 103, 7829-7834. Kawakami, Y., Rodriguez Esteban, C., Raya, M., Kawakami, H., Marti, M., Dubova, I., Izpisua Belmonte, J.C., 2006. Wnt/beta-catenin signaling regulates vertebrate limb regeneration. Genes & development 20, 3232-3237. King, A.E., Umland, E.M., 2008. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28, 667-677. Kinne, R.W., Schmidt-Weber, C.B., Hoppe, R., Buchner, E., Palombo-Kinne, E., Nurnberg, E., Emmrich, F., 1995. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis and rheumatism 38, 1777-1790. Knopf, F., Hammond, C., Chekuru, A., Kurth, T., Hans, S., Weber, C.W., Mahatma, G., Fisher, S., Brand, M., Schulte-Merker, S., Weidinger, G., 2011. Bone regenerates via dedifferentiation of osteoblasts in the zebrafish fin. Developmental cell 20, 713-724. Knothe Tate, M.L., Adamson, J.R., Tami, A.E., Bauer, T.W., 2004. The osteocyte. The international journal of biochemistry & cell biology 36, 1-8. Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., Boyle, W.J., 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176. Laforest, L., Brown, C.W., Poleo, G., Geraudie, J., Tada, M., Ekker, M., Akimenko, M.A., 1998. Involvement of the sonic hedgehog, patched 1 and bmp2 genes in patterning of the zebrafish dermal fin rays. Development 125, 4175-4184. Lee, Y., Hami, D., De Val, S., Kagermeier-Schenk, B., Wills, A.A., Black, B.L., Weidinger, G., Poss, K.D., 2009. Maintenance of blastemal proliferation by functionally diverse epidermis in regenerating zebrafish fins. Developmental biology 331, 270-280. Lehenkari, P.P., Kellinsalmi, M., Napankangas, J.P., Ylitalo, K.V., Monkkonen, J., Rogers, M.J., Azhayev, A., Vaananen, H.K., Hassinen, I.E., 2002. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Molecular pharmacology 61, 1255-1262. Levy, R.J., Schoen, F.J., Lund, S.A., Smith, M.S., 1987. Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Experimental studies of optimal dosages and therapeutic durations. The Journal of thoracic and cardiovascular surgery 94, 551-557. Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Downs, R.W., Jr., Dequeker, J., Favus, M., 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. The New England journal of medicine 333, 1437-1443. Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G., Rogers, M.J., 1998. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 13, 581-589. Lufkin, E.G., Argueta, R., Whitaker, M.D., Cameron, A.L., Wong, V.H., Egan, K.S., O'Fallon, W.M., Riggs, B.L., 1994. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 4, 320-322. Manolagas, S.C., Parfitt, A.M., 2010. What old means to bone. Trends in endocrinology and metabolism: TEM 21, 369-374. Mariotti, A., 2008. Bisphosphonates and osteonecrosis of the jaws. Journal of dental education 72, 919-929. Marx, R.E., 2003. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 61, 1115-1117. Marx, R.E., Sawatari, Y., Fortin, M., Broumand, V., 2005. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 63, 1567-1575. Migliorati, C.A., 2003. Bisphosphanates and oral cavity avascular bone necrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21, 4253-4254. Migliorati, C.A., Schubert, M.M., Peterson, D.E., Seneda, L.M., 2005. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104, 83-93. Migliorati, C.A., Siegel, M.A., Elting, L.S., 2006. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. The lancet oncology 7, 508-514. Miles, A.E., 1972. Phosphorus necrosis of the jaw: 'phossy jaw'. British dental journal 133, 203-206. Mitrofan, L.M., Castells, F.B., Pelkonen, J., Monkkonen, J., 2010. Lysosomal-mitochondrial axis in zoledronic acid-induced apoptosis in human follicular lymphoma cells. The Journal of biological chemistry 285, 1967-1979. Muhlemann, H.R., Bowles, D., Schait, A., Bernimoulin, J.P., 1970. Effect of diphosphonate on human supragingival calculus. Helvetica odontologica acta 14, 31-33. Murakami, H., Takahashi, N., Sasaki, T., Udagawa, N., Tanaka, S., Nakamura, I., Zhang, D., Barbier, A., Suda, T., 1995. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17, 137-144. Murshed, M., Harmey, D., Millan, J.L., McKee, M.D., Karsenty, G., 2005. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes & development 19, 1093-1104. Naik, N.H., Russo, T.A., 2009. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 49, 1729-1732. Nechiporuk, A., Keating, M.T., 2002. A proliferation gradient between proximal and msxb-expressing distal blastema directs zebrafish fin regeneration. Development 129, 2607-2617. Passeri, M., Baroni, M.C., Pedrazzoni, M., Pioli, G., Barbagallo, M., Costi, D., Biondi, M., Girasole, G., Arlunno, B., Palummeri, E., 1991. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone and mineral 15, 237-247. Paterson, A.H., Powles, T.J., Kanis, J.A., McCloskey, E., Hanson, J., Ashley, S., 1993. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 11, 59-65. Pecherstorfer, M., Herrmann, Z., Body, J.J., Manegold, C., Degardin, M., Clemens, M.R., Thurlimann, B., Tubiana-Hulin, M., Steinhauer, E.U., van Eijkeren, M., Huss, H.J., Thiebaud, D., 1996. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 14, 268-276. Plotkin, L.I., Aguirre, J.I., Kousteni, S., Manolagas, S.C., Bellido, T., 2005. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. The Journal of biological chemistry 280, 7317-7325. Plotkin, L.I., Bivi, N., Bellido, T., 2011. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone 49, 122-127. Plotkin, L.I., Manolagas, S.C., Bellido, T., 2002. Transduction of cell survival signals by connexin-43 hemichannels. The Journal of biological chemistry 277, 8648-8657. Plotkin, L.I., Manolagas, S.C., Bellido, T., 2006. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39, 443-452. Plotkin, L.I., Weinstein, R.S., Parfitt, A.M., Roberson, P.K., Manolagas, S.C., Bellido,T., 1999. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. The Journal of clinical investigation 104, 1363-1374. Pollard, M., Luckert, P.H., 1985. Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells. Journal of the National Cancer Institute 75, 949-954. Poss, K.D., Keating, M.T., Nechiporuk, A., 2003. Tales of regeneration in zebrafish. Developmental dynamics : an official publication of the American Association of Anatomists 226, 202-210. Poss, K.D., Shen, J., Nechiporuk, A., McMahon, G., Thisse, B., Thisse, C., Keating, M.T., 2000. Roles for Fgf signaling during zebrafish fin regeneration. Developmental biology 222, 347-358. Quint, E., Smith, A., Avaron, F., Laforest, L., Miles, J., Gaffield, W., Akimenko, M.A., 2002. Bone patterning is altered in the regenerating zebrafish caudal fin after ectopic expression of sonic hedgehog and bmp2b or exposure to cyclopamine. Proceedings of the National Academy of Sciences of the United States of America 99, 8713-8718. Ravn, P., Clemmesen, B., Riis, B.J., Christiansen, C., 1996. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19, 527-533. Recker, R., Masarachia, P., Santora, A., Howard, T., Chavassieux, P., Arlot, M., Rodan, G., Wehren, L., Kimmel, D., 2005. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Current medical research and opinion 21, 185-194. Reid, I.R., 2009. Osteonecrosis of the jaw: who gets it, and why? Bone 44, 4-10. Reid, I.R., King, A.R., Alexander, C.J., Ibbertson, H.K., 1988. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1, 143-146. Roelofs, A.J., Coxon, F.P., Ebetino, F.H., Lundy, M.W., Henneman, Z.J., Nancollas, G.H., Sun, S., Blazewska, K.M., Bala, J.L., Kashemirov, B.A., Khalid, A.B., McKenna, C.E., Rogers, M.J., 2010. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 25, 606-616. Roelofs, A.J., Thompson, K., Gordon, S., Rogers, M.J., 2006. Molecular mechanisms of action of bisphosphonates: current status. Clinical cancer research : an official journal of the American Association for Cancer Research 12, 6222s-6230s. Rogers, M.J., 2003. New insights into the molecular mechanisms of action of bisphosphonates. Current pharmaceutical design 9, 2643-2658. Rosenblum, I.Y., Black, H.E., Ferrell, J.F., 1977. The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcified tissue research 23, 151-159. Rubin, J., Rubin, C., Jacobs, C.R., 2006. Molecular pathways mediating mechanical signaling in bone. Gene 367, 1-16. Ruggiero, S., Gralow, J., Marx, R.E., Hoff, A.O., Schubert, M.M., Huryn, J.M., Toth, B., Damato, K., Valero, V., 2006a. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of oncology practice / American Society of Clinical Oncology 2, 7-14. Ruggiero, S.L., 2008. Bisphosphonate-related osteonecrosis of the jaws. Compend Contin Educ Dent 29, 96-98, 100-102, 104-105. Ruggiero, S.L., Fantasia, J., Carlson, E., 2006b. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 102, 433-441. Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J., Engroff, S.L., 2004. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 62, 527-534. Sanders, J.M., Ghosh, S., Chan, J.M., Meints, G., Wang, H., Raker, A.M., Song, Y., Colantino, A., Burzynska, A., Kafarski, P., Morita, C.T., Oldfield, E., 2004. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. Journal of medicinal chemistry 47, 375-384. Santamaria, J.A., Becerra, J., 1991. Tail fin regeneration in teleosts: cell-extracellular matrix interaction in blastemal differentiation. Journal of anatomy 176, 9-21. Sato, M., Grasser, W., 1990. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 5, 31-40. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D.D., Golub, E., Rodan, G.A., 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. The Journal of clinical investigation 88, 2095-2105. Sawatari, Y., Marx, R.E., 2007. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral and maxillofacial surgery clinics of North America 19, 487-498, v-vi. Schenk, R., Merz, W.A., Muhlbauer, R., Russell, R.G., Fleisch, H., 1973. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcified tissue research 11, 196-214. Schibler, D., Russell, R.G., Fleisch, H., 1968. Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats. Clinical science 35, 363-372. Sewing, L., Steinberg, F., Schmidt, H., Goke, R., 2008. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis : an international journal on programmed cell death 13, 782-789. Singh, S.P., Holdway, J.E., Poss, K.D., 2012. Regeneration of amputated zebrafish fin rays from de novo osteoblasts. Developmental cell 22, 879-886. Sousa, S., Afonso, N., Bensimon-Brito, A., Fonseca, M., Simoes, M., Leon, J., Roehl, H., Cancela, M.L., Jacinto, A., 2011. Differentiated skeletal cells contribute to blastema formation during zebrafish fin regeneration. Development 138, 3897-3905. Stoick-Cooper, C.L., Moon, R.T., Weidinger, G., 2007a. Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine. Genes & development 21, 1292-1315. Stoick-Cooper, C.L., Weidinger, G., Riehle, K.J., Hubbert, C., Major, M.B., Fausto, N., Moon, R.T., 2007b. Distinct Wnt signaling pathways have opposing roles in appendage regeneration. Development 134, 479-489. Sturzenberger, O.P., Swancar, J.R., Reiter, G., 1971. Reduction of dental calculus in humans through the use of a dentifrice containing a crystal-growth inhibitor. Journal of periodontology 42, 416-419. Teitelbaum, S.L., 2007. Osteoclasts: what do they do and how do they do it? The American journal of pathology 170, 427-435. Thompson, K., Rogers, M.J., 2004. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19, 278-288. White, J.A., Boffa, M.B., Jones, B., Petkovich, M., 1994. A zebrafish retinoic acid receptor expressed in the regenerating caudal fin. Development 120, 1861-1872. Whitehead, G.G., Makino, S., Lien, C.L., Keating, M.T., 2005. fgf20 is essential for initiating zebrafish fin regeneration. Science 310, 1957-1960. Woo, S.B., Hellstein, J.W., Kalmar, J.R., 2006. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of internal medicine 144, 753-761. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T.,Higashio, K., Udagawa, N., Takahashi, N., Suda, T., 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences of the United States of America 95, 3597-3602. Yoshinari, N., Kawakami, A., 2011. Mature and juvenile tissue models of regeneration in small fish species. The Biological bulletin 221, 62-78. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/64637 | - |
dc.description.abstract | 雙磷酸鹽藥物主要的藥理作用為抑制蝕骨細胞的骨吸收作用,因此被大量的運用在治療骨質疏鬆症和預防癌症的骨轉移。然而,在長期使用雙磷酸鹽藥物的病患中,卻發現部分病患在拔牙過後,竟會造成顎骨壞死的副作用現象(bisphosphonate-related osteonecrosis of the jaw, BRONJ)。部分假說認為顎骨壞死可能是由於雙磷酸鹽藥物降低蝕骨細胞的活性,進而降低骨頭的代謝(turnover rate),因此產生BRONJ現象;另有假說認為,累積在骨頭的雙磷酸鹽濃度對於口腔上皮組織是有毒性的,導致軟組織傷口的癒合不完全。但BRONJ實際的致病機制還未明瞭。
我們實驗室選用斑馬魚作為模式動物,以其尾鰭再生之特性,切除部分尾鰭模擬傷口的形成,探討在再生組織中,雙磷酸鹽藥物alendronate對於骨骼及上皮等組織的影響,希望能利用in vivo的研究來證實BRONJ的致病機制。 之前本實驗室在形態學上的觀察中,發現雙磷酸鹽藥物alendronate對於成魚尾鰭再生有dose-dependent的影響,低濃度的雙磷酸鹽能促進斑馬魚尾鰭再生時骨頭生長;而高濃度的雙磷酸鹽則能抑制生長。另外,也發現alendronate會在斑馬魚尾鰭再生處造成細胞死亡的現象(吳俊學,2009)。 因此,我以斑馬魚為實驗動物,將斑馬魚的尾鰭進行部分切除後,浸泡於低濃度(2.5×10-5M)及高濃度(7.5×10-5M)之alendronate中,觀察不同濃度之alendronate對於斑馬魚尾鰭再生組織之影響。實驗設計分為三部分,首先,以DNA鹼基類似物EdU (5-ethynyl-2'-deoxyuridine)浸泡於上述以alendronate藥物作用之斑馬魚,再由帶有螢光團的特定小分子,與EdU專一性結合後,可藉著螢光表現得知再生組織區域細胞增生的情形。再來,以綠色螢光蛋白標定造骨細胞的轉殖斑馬魚(Osterix promoter-GFP),切除魚鰭後浸泡於不同濃度之alendronte藥物中,觀察在不同天數中(第3、5、7、9及11天),綠色螢光表現之變化,得知造骨細胞在再生區域受到alendronte藥物作用的情形。最後,利用原位雜合反應,觀察斑馬魚魚鰭再生組織中,Runx2b、Runx2a及Collagen 10a1基因的表現,得知不同濃度的alendronate對於造骨細胞分化時造成的影響。 實驗結果顯示,alendronate在in vivo中會對細胞增生有dose-dependent 的影響:低濃度alendronate能促進前期(截尾第三天時)(3 dpa, day-post-amputation)再生組織中細胞的增生,進而促使之後骨頭的再生;而高濃度alendronate則會抑制前期再生組織中細胞的增生,進而抑制之後骨頭的再生。另外,以綠色螢光蛋白標定造骨細胞的轉殖斑馬魚(Osterix promoter-GFP)觀察中發現,在造骨細胞中,高濃度alendronate會抑制再生組織中造骨細胞增生,促進造骨細胞死亡,影響骨生成作用。進一步利用原位雜合反應觀察斑馬魚魚鰭再生組織中,Runx2b、Runx2a及Collagen 10a1基因表現,結果發現alendronae並不會明顯地影響造骨細胞的分化,所以不是藉由影響造骨細胞的分化而影響骨生成作用。由以上結果推得結論,造成BRONJ的原因,不僅僅只是雙磷酸鹽抑制蝕骨細胞活性,降低骨頭的turnover rate;在活體實驗中發現,高濃度雙磷酸鹽藥物也會對造骨細胞產生影響,抑制造骨細胞的增生而非影響其分化,影響正常的骨生成作用。 | zh_TW |
dc.description.abstract | The main mechanism of bisphosphonate on bone is to inhibit osteoclast-related bone resorption. Bisphosphonates have been prevalently applied in treatment of osteoporosis and prevention of bone metastasis. However, after tooth extraction, the patients who have taken long-term bisphosphonate treatment will appear the osteonecrosis of jaw (bisphosphonate-related osteonecrosis of the jaw, BRONJ). Some studies suggest that bisphosphnates impede the activity of osteoclast, then decrease the bone turnover rate, and finally lead to osteonecrosis of the jaw bone. Other studies also indicate that accumulated bisphosphonates are toxic to epithelium cell, resulting in incomplete soft tissue wound healing. However, the in vivo mechanism of BRONJ is still elusive.
We choose zebrafish as the animal model, amputate the zebrafish caudal fin, and then treat with different concentration alendronate. Finally, we explore the effects of alendronate in the regeneration tissue to uncover the in vivo mechanism of BRONJ. Our previous studies have shown that alendronate is dose-dependent in regeneration of zebrafish caudal fin:low concentration of alendronate promotes bone regeneration, while high concentration of alendronate inhibits bone regeneration. Moreover, alendronate can also induce cell apoptosis in regeneration tissue of zebrafish caudal fin (Wu, 2009). In this study, I amputate the zebrafish caudal fin, and then treat them with low and high concentrations of alendronate (2.5×10-5M and 7.5×10-5M). The experiments are divided into three parts. First, DNA analog Edu (5-ethynyl-2'-deoxyuridine), which can bind with specific flourescent molecule (Alexa488), mark the cell proliferation site. EdU labeling revealed the cell proliferation in regeneration tissue. Second, I use the transgenic zebrafish (Osterix promoter-GFP) to observe the GFP expression in osteoblast under the treatment of alendronate. Finally, I perform in situ hybridization to detect early and late gene markers of osteoblast to unveil the gene expression patterns. My results show that alendronate has a dose-dependent effect in cell proliferation. Low concentration of alendronate increase cell proliferation, and further promote bone regeneration; high concentration of alendronte decrease cell proliferation, further inhibit bone regeneration. Moreover, by observing GFP-labeled osteoblast in transgenic zebrafish, I found that high concentration alendronate can inhibit osteoblast proliferation in regeneration tissue and induce osteoblast apoptosis. Furthermore, in situ hybridization experiments have demonstrated that alendronte doesn’t affect the differentiation of ostoblast. In conclusion, the studies revealed that alendronate inhibits proliferation and survival of osteoblast, but not differentiation, and leads to abnormality and retardation of bone regeneration. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T22:56:48Z (GMT). No. of bitstreams: 1 ntu-101-R99450009-1.pdf: 1718028 bytes, checksum: 81c0b7309879e3891baaead4ae1841f4 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員審定書…………………………………………………i
誌謝……………………………………………………………………ii 中文摘要…………………………………………………………iii 英文摘要………………………………………………………………v 壹、前言………………………………………………………………1 貳、實驗材料……………………………………………………22 參、實驗方法……………………………………………………26 肆、結果……………………………………………………………32 伍、討論……………………………………………………………36 陸、結論……………………………………………………………40 柒、未來展望與研究方向…………………………… 41 捌、圖表……………………………………………………………42 參考文獻……………………………………………………………46 | |
dc.language.iso | zh-TW | |
dc.title | 利用斑馬魚尾鰭再生探討雙磷酸鹽藥物造成顎骨壞死的致病機制-造骨細胞增生和分化的影響 | zh_TW |
dc.title | Unraveling the mechanism of bisphosphonate- related osteonecrosis of the jaw using the regeneration of zebrafish caudal fin as a model | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 王若松,姚宗珍 | |
dc.subject.keyword | 骨壞死,雙磷酸鹽,斑馬魚,造骨細胞, | zh_TW |
dc.subject.keyword | bisphosphonate,osteonecrosis,zebrafish,osteoblast, | en |
dc.relation.page | 56 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-08-10 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.68 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。